PrEP raises first tranche of L21M series A

Infectious disease play PrEP Biopharm Ltd. (London, UK) raised an undisclosed amount in the first tranche of a planned L21 million ($32.4 million) series A round led by hVIVO plc (AIM:HVO), Johnson & Johnson Innovation-JJDC Inc. and U.S.-based angel investors. PrEP expects the second and final close in January 2016.

hVIVO said it is investing L14 million ($21.6 million). ...